Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.33 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31632247 | 0.86 | MAPT (0.39) | MAPTTHRBMAPK1ALDH1A1TSHR | |
| SCHEMBL9766041 | 0.85 | CA1 (0.36) | MAPTTHRBMAPK1ALDH1A1CA1 | |
| SCHEMBL2687218 | 0.84 | PKM (0.41) | MAPTALDH1A1CA1CA2CA4 | |
| SCHEMBL18894092 | 0.79 | MAPK1 (0.39) | MAPTTHRBMAPK1ALDH1A1PKM | |
| SCHEMBL1978032 | 0.79 | MAPT (0.46) | MAPTTHRBMAPK1ALDH1A1TSHR | |
| SCHEMBL1994831 | 0.78 | TDP1 (0.41) | ALDH1A1CA1CA2CA4TSHR | |
| SCHEMBL6182340 | 0.74 | CYP3A4 (0.35) | MAPTTHRBMAPK1ALDH1A1TSHR | |
| SCHEMBL823828 | 0.74 | CES2 (0.43) | MAPTMAPK1ALDH1A1CA1CA2 | |
| SCHEMBL31632378 | 0.73 | GRIN2D (0.42) | MAPTTHRBMAPK1ALDH1A1TSHR | |
| SCHEMBL935587 | 0.73 | ALDH1A1 (0.43) | MAPTALDH1A1TSHRGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034856-B2 | 17-(1′propenyl)-17-3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| US-8987239-B2 | 19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives | Bayer Intellectual Property GbmH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2238149-B1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER IP GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8937058-B2 | 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivative, use thereof, and medicament containing the derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8623850-B2 | 15, 16-methylene-17-(1′-propenyl)-17,3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8445469-B2 | 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-2238147-B1 | 17-(1'-PROPENYL)-17-3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-2238148-B1 | 15,16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-2178899-B1 | 17BETA-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, USE THEREOF AND MEDICAMENTS CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-5519027-A | PROGESTERONE ANTAGONIST FOR OXYTOCICS OR PREVENTION OF TERMINATION OF PREGNANCY | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-05-21 | — | — | US | disclosed |
| WO-1995027726-A1 | 10,11-C3-BRIDGED STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-10-19 | — | — | WO | disclosed |
| WO-1995027725-A1 | 11β,19-BRIDGED 13α-ALKYL STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-10-19 | — | — | WO | disclosed |
| EP-0664811-A1 | GESTAGENICALLY ACTIVE 19,11-BRIDGED 4-ESTRENES. | SCHERING AG (DE) | 1995-08-02 | — | — | EP | disclosed |
| US-5426102-A | Antigestagenic, antiandrogenic, antiglucocorticoid, antimineralcorticoid properties | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-06-20 | — | — | US | disclosed |
| WO-1994009025-A1 | GESTAGENICALLY ACTIVE 19,11-BRIDGED 4-ESTRENES | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-04-28 | — | — | WO | disclosed |
| EP-0567472-A1 | D-HOMO-(16-EN)-11 BETA-ARYL-4-ESTRENES, PROCESS FOR PRODUCING THEM AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1993-11-03 | — | — | EP | disclosed |
| WO-1992011279-A1 | D-HOMO-(16-EN)-11β-ARYL-4-ESTRENES, PROCESS FOR PRODUCING THEM AND THEIR USE AS MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1992-07-09 | — | — | WO | disclosed |
| EP-0298020-B1 | USE OF AN EPOXIDATION REAGENT, AND PROCESS FOR THE PREPARATION OF 5-ALPHA (10-ALPHA) EPOXY-DELTA 9(11) STEROIDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-06-24 | — | — | EP | disclosed |
| EP-0298020-A1 | Use of an epoxidation reagent, and process for the preparation of 5-alpha (10-alpha) epoxy-delta 9(11) steroids | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | HSD17B7, CYP17A1, NR3C2 | MAPT 4510/4885THRB 178/4885MAPK1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.